The metabolism of Alogliptin can be decreased when combined with Olaparib. The risk or severity of adverse effects can be increased when Ondansetron is combined with Etidocaine. The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine. The metabolism of Tacrolimus can be decreased when combined with Atomoxetine. The metabolism of Lornoxicam can be decreased when combined with Pyrimethamine. The therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketorolac. The serum concentration of Plicamycin can be decreased when it is combined with Carbenicillin. The risk or severity of adverse effects can be increased when Zofenopril is combined with SRT501. The risk or severity of adverse effects can be increased when Indiplon is combined with Levocabastine. The risk or severity of adverse effects can be increased when Reserpine is combined with Digoxin Immune Fab (Ovine). The risk or severity of adverse effects can be increased when Reserpine is combined with Papaverine. Bisoprolol may increase the hypotensive activities of Naftopidil. The serum concentration of Cerivastatin can be increased when it is combined with Rolitetracycline. The risk or severity of adverse effects can be increased when Ketorolac is combined with Prednisolone. The metabolism of Oxazepam can be decreased when combined with Cobicistat. Brimonidine may increase the antihypertensive activities of Hydrochlorothiazide. Procarbazine may increase the hypotensive activities of Valsartan. Atomoxetine may increase the hypertensive activities of Etilefrine. The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Quetiapine. The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Penbutolol. Salbutamol may increase the QTc-prolonging activities of Pentamidine. The metabolism of Prochlorperazine can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Quinethazone is combined with Sulpiride. Indacaterol may increase the QTc-prolonging activities of Clozapine. The metabolism of Morphine can be increased when combined with Secobarbital. The risk or severity of adverse effects can be increased when Benzocaine is combined with Prilocaine. Vilanterol may increase the QTc-prolonging activities of Bedaquiline. The serum concentration of Rosuvastatin can be increased when it is combined with Iloperidone. The risk or severity of adverse effects can be increased when Salicylic acid is combined with Anecortave. The risk or severity of adverse effects can be increased when Nalbuphine is combined with Indapamide. The serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox. The risk or severity of adverse effects can be increased when Moexipril is combined with Isoxicam. Dihydrotestosterone may increase the hypoglycemic activities of Pioglitazone. The serum concentration of Cerivastatin can be increased when it is combined with Lidocaine. The serum concentration of Ramelteon can be increased when it is combined with Ivacaftor. The metabolism of Aminophenazone can be decreased when combined with Paroxetine. The serum concentration of Conivaptan can be increased when it is combined with Dutasteride. Pargyline may increase the hypertensive activities of Dextroamphetamine. The risk or severity of adverse effects can be increased when Quinidine is combined with Atorvastatin. Pargyline may increase the hypotensive activities of Acebutolol. The bioavailability of Flurandrenolide can be decreased when combined with Magnesium Trisilicate. The metabolism of Roxithromycin can be decreased when combined with Darunavir. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam. Cyclizine may increase the sedative activities of Pramipexole. The risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate. The risk or severity of adverse effects can be increased when Dyclonine is combined with Meclizine. The metabolism of Vandetanib can be decreased when combined with Clemastine. Hydroflumethiazide may decrease the excretion rate of Lithium which could result in a higher serum level. The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diazoxide. The risk or severity of adverse effects can be increased when Quazepam is combined with Levodopa. The therapeutic efficacy of Propantheline can be decreased when used in combination with 1,10-Phenanthroline. The metabolism of Clotiazepam can be decreased when combined with Sulfisoxazole. Salicylic acid may decrease the antihypertensive activities of Zofenopril. The metabolism of Alclometasone can be decreased when combined with Erythromycin. Arformoterol may increase the QTc-prolonging activities of Quinidine. The serum concentration of Flurandrenolide can be increased when it is combined with Indinavir. Adapalene may decrease the antihypertensive activities of Labetalol. Hydroflumethiazide may increase the hypotensive activities of Tibolone. Parecoxib may increase the thrombogenic activities of Methallenestril. The risk or severity of adverse effects can be increased when Methohexital is combined with Flunarizine. Dihydralazine may increase the hypotensive activities of Timolol. The risk or severity of adverse effects can be increased when Cinchocaine is combined with Dextropropoxyphene. The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Azilsartan medoxomil. The serum concentration of Prednisolone can be increased when it is combined with Lopinavir. The metabolism of Dienogest can be decreased when combined with Imatinib. The risk or severity of adverse effects can be increased when Forasartan is combined with Ketorolac. Alfuzosin may increase the hypotensive activities of Reserpine. Nimesulide may increase the neuroexcitatory activities of Trovafloxacin. The metabolism of Pentobarbital can be decreased when combined with Armodafinil. The therapeutic efficacy of Linagliptin can be decreased when used in combination with Diazoxide. The serum concentration of Levobupivacaine can be increased when it is combined with Simeprevir. The metabolism of Netupitant can be decreased when combined with Irbesartan. Indoramin may increase the hypotensive activities of Verapamil. The risk or severity of adverse effects can be increased when Benzydamine is combined with Amcinonide. The serum concentration of Rilpivirine can be decreased when it is combined with Mitotane. The serum concentration of Rimexolone can be increased when it is combined with Estrone. The serum concentration of Desonide can be increased when it is combined with Estrone. The serum concentration of Tolbutamide can be increased when it is combined with Ranitidine. The serum concentration of Rilpivirine can be decreased when it is combined with Rifabutin. The metabolism of Cyclosporine can be decreased when combined with Artemether. Resveratrol may decrease the antihypertensive activities of Metipranolol. The serum concentration of Desoximetasone can be decreased when it is combined with Enzalutamide. Benoxaprofen may increase the anticoagulant activities of Heparin. The serum concentration of Finasteride can be increased when it is combined with Aprepitant. The risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil. The risk or severity of adverse effects can be increased when Clonidine is combined with Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Indoramin is combined with Tamsulosin. The metabolism of Palonosetron can be decreased when combined with Ritonavir. The therapeutic efficacy of Nadroparin can be decreased when used in combination with Medroxyprogesterone acetate. The risk or severity of adverse effects can be increased when Saprisartan is combined with Meclofenamic acid. The risk or severity of adverse effects can be increased when Fentanyl is combined with Etomidate. Azelastine may increase the antiplatelet activities of Butylphthalide. The risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone furoate. The risk or severity of adverse effects can be increased when Ibuproxam is combined with Fluocinolone Acetonide. The risk or severity of adverse effects can be increased when Olmesartan is combined with Clonidine. The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Levonorgestrel. The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Carprofen. The metabolism of Loperamide can be decreased when combined with Efavirenz. Trastuzumab may increase the cardiotoxic activities of Ciprofloxacin. The therapeutic efficacy of Atropine can be decreased when used in combination with Distigmine. The therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Dydrogesterone. Azithromycin may increase the QTc-prolonging activities of Paliperidone. Triptolide may increase the nephrotoxic activities of Cyclosporine. The metabolism of Chlorzoxazone can be decreased when combined with Dihydroergotamine. The risk or severity of adverse effects can be increased when Cocaine is combined with Etifoxine. The serum concentration of Mirtazapine can be increased when it is combined with Ivacaftor. The therapeutic efficacy of Levodopa can be decreased when used in combination with Perospirone. The metabolism of Lansoprazole can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Rimexolone is combined with Memantine. The metabolism of Betaxolol can be decreased when combined with Azithromycin. The risk or severity of adverse effects can be increased when Lidocaine is combined with Pramocaine. Heparin may increase the hyperkalemic activities of Sacubitril. Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Salicylic acid may increase the neuroexcitatory activities of Pazufloxacin. The risk or severity of adverse effects can be increased when Allopregnanolone is combined with Dexbrompheniramine. The serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide. Levodopa may increase the sedative activities of Ropinirole. The serum concentration of Mometasone can be decreased when it is combined with Pentobarbital. The serum concentration of Dextropropoxyphene can be increased when it is combined with Aprepitant. Imipramine may increase the orthostatic hypotensive activities of Levodopa. The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Amobarbital. Mesterolone may increase the hypoglycemic activities of Dapagliflozin. The serum concentration of Dyphylline can be decreased when it is combined with Sitagliptin. Diflunisal may decrease the excretion rate of Gentamicin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Andrographolide is combined with Carbaspirin calcium. The metabolism of Brinzolamide can be decreased when combined with Delavirdine. The risk or severity of adverse effects can be increased when Cilazapril is combined with Andrographolide. The serum concentration of Ciclesonide can be increased when it is combined with Dienestrol. Risperidone may increase the QTc-prolonging activities of Erythromycin. The metabolism of Zileuton can be decreased when combined with Tolbutamide.